Lesson plan
Odapipam
Odapipam ( ; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D 1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed. It has more than 5,000-fold selectivity for the dopamine D 1 receptor (K i = 0.17 nM) over the dopamine D 2 receptor (K i = 942 nM). Its affinities for other dopamine receptors, such as the dopamine D 5 receptor, were not reported. In addition to the dopamine D 1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT 2 receptor (K i = 4.5 nM; 26-fold lower than for the D 1 receptor). The drug was first described in the scientific literature by 1988.
Article summary
Odapipam ( ; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D 1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed. It has more than 5,000-fold selectivity for the dopamine D 1 receptor (K i = 0.17 nM) over the dopamine D 2 receptor (K i = 942 nM). Its affinities for other dopamine receptors, such as the dopamine D 5 receptor, were not reported. In addition to the dopamine D 1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT 2 receptor (K i = 4.5 nM; 26-fold lower than for the D 1 receptor). The drug was first described in the scientific literature by 1988.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.